Senior White House officials have raised objections to the U.S. Food and Drug Administration’s proposed standards for deciding whether a Covid-19 vaccine should be given widely and don’t appear likely to sign off on the agency’s guidelines, people familiar with the matter said.
In talks with the FDA in recent days, White House officials expressed a number of concerns about the draft guidelines, including a proposal that would require researchers to monitor study subjects for side effects for two months after getting a shot,…